ES8605039A1 - Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos. - Google Patents

Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.

Info

Publication number
ES8605039A1
ES8605039A1 ES535554A ES535554A ES8605039A1 ES 8605039 A1 ES8605039 A1 ES 8605039A1 ES 535554 A ES535554 A ES 535554A ES 535554 A ES535554 A ES 535554A ES 8605039 A1 ES8605039 A1 ES 8605039A1
Authority
ES
Spain
Prior art keywords
making
membrane bound
bound proteins
vaccines based
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES535554A
Other languages
English (en)
Other versions
ES535554A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27414978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8605039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES8605039A1 publication Critical patent/ES8605039A1/es
Publication of ES535554A0 publication Critical patent/ES535554A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR UNA VACUNA QUE COMPRENDE UN DERIVADO TRUNCADO, LIBRE DE MEMBRANA, DE UN POLIPEPTIDO FIJADO A UNA MEMBRANA, CON DETERMINANTES ANTIGENICOS EXPUESTOS. COMPRENDE PREPARAR UN ADN (ACIDO DESOXIRRIBONUCLEICO) QUE CODIFICA EL POLIPEPTIDO FIJADO A UNA MEMBRANA, QUE CARECE DE CODIFICACION PARA DOMINIO DE FIJACION A MEMBRANAS; INCORPORAR EL ADN A UN VECTOR DE EXPRESION; TRANSFECTAR UNA CELULA HOSPEDANTE, TAL COMO UNA LINEA DE CELULAS EUCARIOTICAS ESTABLES, CON DICHO VECTOR; Y RECOGER EL POLIPEPTIDO TRUNCADO COMO UN PRODUCTO DE SECRECION; DONDE LA LINEA DE CELULAS ES DEFICIENTE EN LA PRODUCCION DE DIHIDROFOLATO-REDUCTASA (DHFR), EL VECTOR CONTIENE UN MARCADOR SELECCIONABLE PARA DHFR Y EL POLIPEPTIDO TRUNCADO E SUN DERIVADO DE UNA GLICOPROTEINA D DE UN VIRUS DE HERPES SIMPLEX DE TIPO 1 O TIPO 2.
ES535554A 1983-08-30 1984-08-30 Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos. Expired ES8605039A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52791783A 1983-08-30 1983-08-30
US54755183A 1983-10-31 1983-10-31
US58817084A 1984-03-09 1984-03-09

Publications (2)

Publication Number Publication Date
ES8605039A1 true ES8605039A1 (es) 1986-03-16
ES535554A0 ES535554A0 (es) 1986-03-16

Family

ID=27414978

Family Applications (2)

Application Number Title Priority Date Filing Date
ES535554A Expired ES8605039A1 (es) 1983-08-30 1984-08-30 Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.
ES552539A Expired ES8705036A1 (es) 1983-08-30 1986-02-28 Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES552539A Expired ES8705036A1 (es) 1983-08-30 1986-02-28 Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana

Country Status (13)

Country Link
US (1) US5851533A (es)
EP (1) EP0139417B2 (es)
JP (2) JP2599350B2 (es)
AU (1) AU579323B2 (es)
CA (1) CA1341181C (es)
DE (1) DE3479085D1 (es)
DK (2) DK172694B1 (es)
ES (2) ES8605039A1 (es)
GR (1) GR80220B (es)
HK (1) HK98792A (es)
IE (1) IE58030B1 (es)
IL (1) IL72785A (es)
NZ (1) NZ209308A (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
GR862472B (en) * 1986-09-30 1986-10-09 Elliniko Institouto Paster Determination of antibodies specific of hsv-1 herpes or hsv-2 in human serum with the elisa technic using the specific antigen of hsv-1 or hsv-2 type in semi - clean form
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
EP0471778A1 (en) * 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
JPH05501951A (ja) * 1989-07-31 1993-04-15 ニコルズ　インスティテュート　ダイアグノスティクス 組換えヒト甲状腺ペルオキシダーゼ
JP3005292B2 (ja) * 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
JPH07506960A (ja) * 1991-08-28 1995-08-03 ニコルス・インスティチュート・ダイアグノスティクス ヒト甲状腺ペルオキシダーゼに特異的な疾病関連性ヒト抗体
JP3755890B2 (ja) * 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AU2001286407A1 (en) * 2000-08-01 2002-03-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiviral compounds derived from the hsv gd protein and methods
DK2248822T3 (en) 2001-07-27 2017-02-13 Glaxosmithkline Biologicals Sa MENINGOCOKKER ADHESIONS
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US7540902B2 (en) 2004-11-24 2009-06-02 Shell Oil Company Separator for multi-phase slug flow and method of designing same
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
EP2059255A4 (en) 2006-09-08 2011-08-31 Univ Pennsylvania VACCINES AGAINST HSV-1 AND HSV-2 AND METHODS OF USE
EP2114449B1 (en) * 2006-12-28 2016-02-17 The Trustees of the University of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP3756684A1 (en) * 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
NZ600323A (en) 2009-12-03 2013-12-20 Novartis Ag Circulation of components during microfluidization and/or homogenization emulsions
KR101643918B1 (ko) 2009-12-03 2016-07-29 노파르티스 아게 미세 액화를 위한 상호작용 및 배압 챔버의 배치
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CN102858322B (zh) 2009-12-03 2015-04-29 诺华股份有限公司 疫苗佐剂制备中的亲水过滤
ES2597158T5 (es) 2010-05-12 2020-03-26 Novartis Ag Procedimientos mejorados para preparar escualeno
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
CN110938604B (zh) * 2014-03-03 2024-04-05 阿尔伯特爱因斯坦医学院 重组单纯疱疹病毒2(hsv-2)疫苗载体
EP3226904B1 (en) 2014-12-02 2019-03-06 Novartis AG Manufacture of surfactant-containing compositions
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
AU2021302954A1 (en) 2020-06-30 2023-02-16 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
FI66020C (fi) * 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
EP0038765B1 (fr) * 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
WO1982003088A1 (en) * 1981-03-09 1982-09-16 Corp Cetus Vaccines
GB2103622B (en) 1981-06-16 1986-01-15 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US4891315A (en) * 1982-10-25 1990-01-02 American Cyanamid Company Production of herpes simplex viral porteins
PT77014B (en) * 1982-07-20 1986-01-24 Molecular Genetics Inc Production of herpes simplex viral proteins
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
DK305784A (da) * 1983-06-23 1984-12-24 Stanley Person Ikke-glycosyleret aminosyrekaede af glycoprotein b fra herpes virus type 1 og 2
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
EP0175787B1 (en) * 1984-04-06 1995-02-15 Chiron Corporation RECOMBINANT HERPES SIMPLEX gB-gD VACCINE
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
JPS615786A (ja) * 1984-06-19 1986-01-11 Chemo Sero Therapeut Res Inst 単純ヘルペスウイルス遺伝子を組込んだ組換えｄｎａ、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法
DE3582200D1 (de) * 1984-07-20 1991-04-25 Chemo Sero Therapeut Res Inst Rekombinante dns, enthaltend ein herpes-simplex-virus-gen oder ein fragment davon, hefe transformiert mit dieser rekombinanten dns und verfahren zur herstellung von herpes-simplex-virus-proteinen.

Also Published As

Publication number Publication date
DK9197A (da) 1997-01-24
EP0139417A1 (en) 1985-05-02
HK98792A (en) 1992-12-18
GR80220B (en) 1984-11-15
DK172694B1 (da) 1999-05-31
IE842210L (en) 1985-02-28
ES8705036A1 (es) 1987-05-01
JPH08253428A (ja) 1996-10-01
AU579323B2 (en) 1988-11-24
JP2599350B2 (ja) 1997-04-09
US5851533A (en) 1998-12-22
ES552539A0 (es) 1987-05-01
JPS60155128A (ja) 1985-08-15
IE58030B1 (en) 1993-06-16
DE3479085D1 (en) 1989-08-31
DK412284D0 (da) 1984-08-29
EP0139417B1 (en) 1989-07-26
CA1341181C (en) 2001-02-20
IL72785A (en) 1990-07-26
EP0139417B2 (en) 1999-03-17
DK412284A (da) 1985-04-11
NZ209308A (en) 1991-08-27
AU3242384A (en) 1985-03-07
ES535554A0 (es) 1986-03-16
IL72785A0 (en) 1984-11-30

Similar Documents

Publication Publication Date Title
ES8705036A1 (es) Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana
SG48422A1 (en) Yeast expression systems with vectors having gapdh promoters and synthesis of hbsag
ES8600649A1 (es) Un metodo de producir una forma geneticamente estable de vidrio cholerae
EP0101506A4 (en) MATERIAL AND METHOD FOR HERPES SIMPLEX VIRUS Vaccination.
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
WO1989007136A3 (en) Modified hepatocytes and uses therefor
ES8405072A1 (es) Un procedimiento para la preparacion de un vector de trans- ferencia dna
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
IL77694A (en) Canine parvovirus vaccines comprising viruses of the canine parvovirus strain 154 or viruses derived therefrom by additional cell culture passaging
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
ES8604693A1 (es) Un metodo para detectar un anticuerpo o un antigeno contenido en una muestra de fluido de origen biologico.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
NO910479D0 (no) Syntetiske polypeptider og antistoffer relatert til epstein-barr-virus-kjerneantigen.
AU5507786A (en) Process for the preparation of an antigen specific to herpes simplex virus type 2, agents suitable for this purpose, and the use of this antigen
ZA831097B (en) Materials and methods for herpes simplex virus vaccination
GT198304126A (es) Produccion de proteinas del virus de herpes simplex

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20051221